Amarin Corp Plc (AMRN)

[mrmainstreet]

If we need 5.2% just to hit the minimum target there's not much wiggle room. Original design was 5.9% placebo rate, but that dropped to as low as 5.2% when they added the extra 1000 patients.

With the trial extending into 2018 let's hope the slow down in events is due to Vascepa and not a lower p-rate.